For a patient weighing 200 pounds, this could translate to a loss of 30 to 34 pounds, representing a transformative change in health and mobility
This paradigm shift would expand the conceptual framework of addiction treatment beyond dopamine-centric models and open new avenues for addressing other substance use disorders, including alcohol, stimulants, and nicotine
J Food Sci 76(8):M568M572
July 2023: Phase 2 trial results indicated observed effects relevant to obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD)
Those antibodies could make future doses less effective, increase the risk of future reactions, or, in some therapeutic proteins, interfere with related natural proteins in the body